Sustained over-activation of RhoA is a common component for the pathogenesis of several cardiovascular disorders including hypertension. Although activity of Rho proteins depends on Rho exchange factors (Rho-GEFs), the identity of Rho-GEFs expressed in vascular smooth muscle cells (VSMC) and participating in the control of Rho protein activity and Rhodependent functions remains unknown. To address this question, we analyzed by quantitative RT-PCR the expression profile of 28 RhoA-GEFs in arteries of normotensive (saline-treated) and hypertensive (Ang II-treated) rats. Sixteen RhoA-GEFs were down-regulated in mesenteric arteries of hypertensive rats, among which nine are also down-regulated in cultured VSMC stimulated by Ang II (100 nM, 48h), suggesting a direct effet of Ang II.
Introduction
The small GTPase RhoA control numerous cellular processes ranging from the regulation of the actin-based cytoskeleton, cell morphology, growth and motility, to nuclear gene expression mostly through the binding to its major effector, Rho-kinase. RhoA/Rhokinase signaling has been recognized as a major regulator of cardiovascular functions, and accumulating evidence described over activity of RhoA as a common component for the pathogenesis of several cardiovascular disorders including hypertension, coronary and cerebral vasospam, atherosclerosis and restenosis (17, 18) . Over activation of RhoA/Rhokinase pathway in vascular smooth muscle cells (VSMC) is involved in the vascular hyperreactivity, excessive migration and proliferation associated with hypertensive diseases (17, 18) .
RhoA acts as molecular switch that cycle between two conformation states. The transition between the inactive GDP-bound form and an active GTP-bound form is mediated by the Rho guanine exchange factors (Rho-GEFs), that catalyze the replacement of GDP by GTP (11) . Rho-GEF activity is regulated by several mechanisms including activation of cell surface receptors such as G protein coupled-and tyrosine kinase-receptors (30, 32) . Because of their strategic position in Rho protein signaling pathway, Rho-GEFs could be considered as key molecules involved in hyperactivity of RhoA occuring in cardiovascular disorders including hypertension (19) . Nevertheless, knowledge on the expression, activity and regulation of Rho-GEFs in VSMC are still limited. It has been reported that the three members of the RGS-containing Rho-GEFs subfamily of Rho-GEFs, namely, Arhgef1 (p115-RhoGEF), Arhgef11 (PDZ-RhoGEF) and Arhgef12 (Larg) are expressed in arteries, with a higher expression of Arhgef11, both at mRNA and protein levels in rat aorta and mesenteric artery, (10, 12, 41) . In contrast, in mice aorta, Arhgef12 has been reported to be the predominant RGS-Rho-GEF, and Arhgef11 was the less expressed (37) . Arhgef12 transcript Manuscript # C-00423-2011 -Revision 4 and protein are undetectable prior to embryonic day 14, but are then expressed in VSMC at later stages of development and in adulthood (2) .
Angiotensin II (Ang II) is one of the most powerful physiological vasoconstrictor which plays a major role in the regulation of blood pressure and was identified as a causative factor in the development and maintenance of hypertension (35) . Recent accumulating evidence suggest that Ang II and type I Ang II receptors (AT1R) participate to the over-activation of RhoA associated with hypertension and that the RhoA/Rho kinase pathway is critical for vascular alteration induced by Ang II in the hypertensive cardiovascular remodeling (13, 17, 27) . Accordingly, several studies were interested in RhoA-GEFs in Ang II-stimulated VSMC or in arteries of Ang II-treated hypertensive animals. Regarding Ang II-mediated regulation of Rho-GEFs activity, we recently demonstrated both in vivo and in vitro that Arhgef1 is activated in arteries from Ang II-infused rats or mice and plays an essential role in Ang IIinduced maintained RhoA activation, vasoconstriction and hypertension (7) . Two other RhoGEFs, p63RhoGef and Arhgef11 have also been shown to be involved in the early RhoA activation induced in vitro by Ang II stimulation of VSMC for 30 s (38) and 3 min (40), respectively. Regarding Ang II-mediated regulation of RhoA-GEF expression, studies essentially focused on the three members of the RGS-containing Rho-GEFs family, suggested to couple vasoconstrictor receptors to RhoA activation in smooth muscle cells (30) , and led to conflicting data. In vitro stimulation of rings or cultured smooth muscle cells from SpragueDawley rat aortas by Ang II induces a transient increase in Arhgef12 expression without any change in Arhgef1 or Arhgef11 expression (42) . In vivo, hypertension induced by Ang II infusion in Sprague-Dawley rats is associated with a decrease in Arhgef11 mRNA expression but an increase in its protein expression in the mesenteric arteries (10) . The expression of Arhgef12 and Arhgef1 is not changed (10) . In the same model, the expression of Arhgef11
Manuscript # C-00423-2011 -Revision 5 and Arhgef1 proteins, and Arhgef1 mRNAs in the aorta has been shown to be not modified, while RhoA protein expression was found to be upregulated (12) .
The aim of this study was to depict the global pattern of RhoA-GEFs expression in VSMCs and its transcriptional remodeling during Ang II-dependent hypertension, and to address the functional consequence of this transcriptional regulation of RhoA-GEFs expression in VSMCs.
Materials and Methods

RNA extraction and cDNA preparation
Total RNA was extracted from male Wistar-Kyoto rat arteries using the RNeasy fibrous tissue RNA extraction midi kit (QIAGEN, Courtaboeuf, France) and from others tissues or VSMCs from mesenteric arteries (MA-SMCs) using TRIzol reagent (Invitrogen, Cergy Pontoise, France) according to the manufacturer's instructions.
Genomic DNA contamination was eliminated with ribonuclease-free deoxyribonuclease (DNAse) I (Invitrogen). Absence of DNA contamination was screened by PCR using glyceraldehydes 3-phosphate dehydrogenase (GAPDH) primers. Complementary DNA libraries were generated from 1 µg of total RNA which was reverse-transcripted using Moloney murine leukaemia virus reverse transcriptase (Invitrogen) and deoxyribonucleic random hexamer as primers (Invitrogen). The cDNA was diluted 20 times in water and used in real-time quantitative PCR experiments.
Real-Time Quantitative PCR
On the basis on sequence homology and bibliographic data, we identified 28 sequences of mRNA of rat GEFs able to activate RhoA in the GenBank nucleotide database. Sequences of specific primers have been designed for QPCR using Oligo6 sofware (Molecular Biology Manuscript # C-00423-2011 -Revision 6 Insights, Cascade, CO, USA). Primers were designed to amplify fragments between 93 and 238 bp. The PCR primers were synthesized by Eurogentec (Liège, Belgium) (Primer sequences can be obtained on request). The expression of RhoA-GEFs was analysed by realtime PCR on the iCycler iQ™ Detection System (Bio-Rad S.A., Marnes la Coquette, France) using Sybr green as fluorescent probe (Molecular Probes, Eugene, OR, USA). A dilution range of the produced cDNA from a RNA pool of MA-SMCs was added to 25 μl quantitative PCR reactions containing 0.5 μl Titanium™ taq DNA polymerase (Clontech), 300 nM genespecific primers or reference house-keeping gene primers, 300 nM of dNTPs and Sybr green (1:25 000). Amplifications were performed in triplicate and started with an initial step of 3 min at 95°C, followed by 40 cycles each consisting of 15 s at 95°C and 1 min at 65°C. The standard curve so obtained was used to check that PCR efficiencies were identical between the interest and reference genes. The fluorescent signals were normalized to GAPDH used as non-variant reference gene, after having checked that the use of two other reference housekeeping genes, β-actin and the ribosomal phosphoprotein P0, gave same results. Relative quantification, following the ΔΔCt-method (6) was applied to compare amounts of mRNA in the different vessels and tissues. RhoA-GEF mRNA expression was expressed relative to that of Vav2 set as 1. Similar approaches were applied to the analysis of RhoA-GEF mRNA expression in MA-SMCs (n = 5 cultures, minimum) and expression of each RhoA-GEF mRNA was expressed relative to that of control or untreated condition.
For human samples, RhoA-GEF expression profiling was performed using 7900HT Micro Fluidic Card and the ABI PRISM® 7900HT Sequence Detection System. The TaqMan probe and primer sets for human RhoA-GEFs and 18S rRNA as a reference gene were selected from pre-designed TaqMan Gene Expression Assays (Applied Biosystems) (Primer sequences can be obtained on request). Micro Fluidic Card experiments use a two-step RT-PCR process. In the reverse-transcription step, cDNA was synthesized from commercially available total RNA 
Animal model and blood pressure measurement
Male Wistar-Kyoto rats (300 g) were implanted with a subcutaneous osmotic minipump (Alzet, Cupertino, California, USA) difusing saline solution (control) or angiotensin II (Ang II) (250 ng/kg/min, Sigma-Aldrich, Lyon, France) for 14 days. A radio telemetry system was used to monitor mean arterial pressure as described previously (22) 
Tissue samples
Aorta, pulmonary artery, mesenteric artery of control or Ang II-treated male Wistarkyoto rats were isolated and cleaned of adherent connective tissue in sterile PSS-HEPES buffer (in mM): 130 NaCl, 5.6 KCl, 1 MgCl 2 , 11 glucose, 10 HEPES, (pH 7.4 with NaOH).
The endothelium was carefully removed by gently rubbing the vessel with the tip of small 
Western blot analysis
Manuscript # C-00423-2011 -Revision 9 MA-SMCs were lysed in NETF lysis buffer (NaCl 100 mM, EGTA 2 mM, Tris-HCl 50 mM, 50 mM NaF, pH 7.4) supplemented with 1% nonidet P-40, 2 mM sodium orthovanadate, protease inhibitor cocktail (P8340, Sigma-Aldrich) and phosphate inhibitor cocktail 3 (P0044, Sigma-Aldrich). Cell fragments were removed by 9000 g centrifugation for 10 min at 4°C.
The protein concentration of the supernatant was determined using BioRad Protein Assay 
RhoA activity
The level of GTP-loaded RhoA has been assessed by pull-down assay with the RhoA G-LISA kits (Cytoskeleton) using the Rho-binding domain of the Rho effector Rhotekin according to the manufacturer's recommendations.
Statistical analysis
All results are expressed as the mean ± S.E.M. with n the sample size. Significance of RT-PCR ratio, western blot studies was tested by student t-test and the one-way or two-way Manuscript # C-00423-2011 -Revision 11 ANOVA completed by the Holm Sidak test when appropriate. Probabilities less than 5% (P<0.05) were considered as significant. All experiments were independently repeated at least three times.
Results
Specific expression pattern of RhoA-GEFs in arteries
The expression profiles of 28 RhoA-GEFs have been established by qPCR in rat aorta, mesenteric and pulmonary arteries (Fig. 1) . The expression profiles of RhoA-GEFs are relatively similar in the three different arteries examined (Fig. 1A-C) . The 8 most expressed
RhoA-GEF mRNAs are the same in the three arteries: p63-RhoGEF, Lbc, Trio, Arhgef12, Arhgef1, Arhgef2, Arhgef17 and Scambio. Then, a group of 13 RhoA-GEF mRNAs showed a moderated expression and displayed more heterogeneity between the three arteries. For example, p190-RhoGEF mRNA showed high expression level in aorta compared to its low level in MA and PA (Fig. 1A-C) . Similar heterogeneity between arteries was also found for Duo and Arhgef18 mRNAs. Finally, 7 RhoA-GEF mRNAs showed a low expression level and the obscurin transcript was not detected in arterial media but was found to be expressed at a high level in skeletal muscle, and to a lesser extend in the heart. More generally, the RhoA-GEF expression pattern in arteries is very different from those found in three other differentiated non-vascular tissues studied namely the heart, skeletal muscle and brain ( Fig.   1D-F) . The expression levels of all RhoA-GEF mRNAs were lower in the heart, striated muscles and brain than in vessels suggesting a distinct involvement of RhoA pathway depending on tissue origin and function. Arhgef12 is the major cardiac RhoA-GEF (Fig. 1D ).
The two most expressed RhoA-GEFs in skeletal muscle are Arhgef14 and obscurin (Fig. 1E) . In brain, the higher mRNAs expression was found for p63-RhoGEF, Arhgef12 and Arhgef2 (Fig. 1F) . Therefore, this RhoA-GEF mRNA expression pattern analysis reveals a RhoA-GEF expression profile specific of arteries that is different from the RhoA-GEF expression profiles of non-vascular tissues. Interestingly, the RhoA-GEF expression profile found in rat arteries is retrieved in human arteries (aorta and renal artery), suggesting a conserved tissue specificity of RhoA-GEF expression (Fig. 2) .
Change in arterial RhoA-GEF mRNA expression pattern in Ang II-induced hypertension
To analyse whether Ang II-induced hypertension is associated with change in RhoA-GEF mRNA profile in arteries, we first measured by qPCR, the expression levels of the 28
RhoA-GEF transcripts in MA of rats treated for 14 days by Ang II. Expression levels of 16
RhoA-GEFs were found to be significantly decreased in MA of Ang II-treated rats, including the 3 RGS-containing RhoA-GEFs (Arhgef1, Arhgef11 and Arhgef12) ( Fig. 3 and Table 1 ).
Five RhoA-GEFs were upregulated and 6 were not modified ( Fig. 3 and Table 1 ). These results revealed a strong remodeling of RhoA-GEF mRNA expression in MA of Ang IItreated rats suggesting that Ang II and/or high blood pressure influenced RhoA-GEF mRNA expression.
Ang II controls RhoA-GEF mRNA expression in MA-SMCs
To assess a direct role of Ang II in the transcriptional regulation of arterial RhoA-GEFs, we next directly examined the effect of Ang II (0.1 µM) on the expression of RhoA-GEFs in MA-SMCs. After 48 h, Ang II stimulation increased the expression of 3 RhoA-GEFs, scambio, p190-RhoGEF and Duo, and downregulated the expression level of 15 RhoA-GEFs ( Fig. 4A and Table 1 ). Comparison of down-regulated RhoA-GEFs in vitro in Ang IIstimulated MA-SMC and in vivo in MA of hypertensive rats led to the selection of 9 RhoAGEFs that were similarly altered in both models (Table 1 ). This observation suggests that these 9 selected GEFs including, Arhgef12, Arhgef1, Arhgef2, Arhgef17, Arhgef11, Manuscript # C-00423-2011 -Revision 13 Arhgef18, Arhgef3, Abr and Dbl were down-regulated by direct Ang II-dependent pathway in vivo. The AT1R antagonist losartan prevented Ang II-mediated decrease of the 9 RhoA-GEF expression in MA-SMC indicated that it was mediated by AT1R activation by Ang II (Fig.   4B ). The efficiency of AT1 inhibition by losartan treatment was assessed by the inhibition of the RhoA/Rho kinase mediated MYPT1 phosphorylation, known to be downstream of AT1R (8) (Fig. 4C ).
We then examined by western blot analysis the protein expression levels of the 3 RGScontaining RhoA-GEFs, for which antibodies are available (Fig. 4D-F) . Immunoreactive bands were detected at the expected size for Arhgef1 (115 kDa), Arhgef11 (~170 kDa) and Arhgef12 (~170 kDa). Expression of Arhgef1 and Arhgef12 were significantly decreased in Ang II-treated MA-SMCs (Fig. 4D, F) , while we did not found a significant change in Arhgef11 protein expression (Fig. 4E) .
Ang II-mediated down-regulation of RhoA-GEFs depends on RhoA/Rho-kinase activation.
We next wanted to identify intracellular signaling downstream to AT1R involved in Ang II-mediated down-regulation of RhoA-GEF mRNA. Although AT1R are coupled to multiple signalling pathways, we first hypothesized that RhoA-GEFs down-regulation could result from a negative feed-back of the RhoA/Rho kinase signaling activated by Ang II (Fig.   4C ). To assess this hypothesis, we performed Ang II stimulation of MA-SMCs in the presence of the Rho kinase inhibitor fasudil. The inhibition of Rho kinase activity, as assessed by the level of MYPT1 phosphorylation (Fig. 5A ) inhibition prevented Ang II-induced downregulation of the 9 RhoA-GEF transcripts (Fig. 5B) , indicating that it was dependent on Ang II/AT1R-mediated Rho kinase activation.
As transactivation of epidermal growth factor receptor (EGFR) is one of the mechanisms by which Ang II influences intracellular signaling pathways (21, 24), we next (Fig. 6A) , that abolished Ang II-induced JNK phosphorylation (Fig. 6B) . NF-kB activation inhibitor, that prevented Ang II-induced NF-κB-dependent transcription, inhibited the decrease in Arhgef12, Arhgef1, Arhgef17 and ABR mRNA expression induced by Ang II (Fig. 6C, D) . To analyse the involvement of P38-MAPK in Ang II-induced RhoA-GEFs down-regulation, MA-SMCs were treated with SB239063. Inhibition of Ang II-induced P38-MAPK activation is associated with the loss of the down-regulation of Arhgef12, Arhgef11 and Dbl (Fig. 6E, F) .
These data suggest that Ang II-induced Rho-kinase-dependent down-expression of RhoA-GEFs simultaneously involved JNK, NFκB and P38-MAPK signaling activity. 
Ang-II induced
Ang-II-downregulated RhoA-GEFs are involved in ET-1, NA and U46619-induced RhoA/Rhokinase activation.
To confirm the role the RhoA-GEFs down-regulated by Ang II in vasoconstrictorinduced RhoA/Rho kinase activation, we assessed the consequences of siRNA-mediated silencing of these RhoA-GEFs on the activation of RhoA induced by stimulation by ET-1, NA and U46619 for 5 and 60 min in MA-SMCs (Table 2) . With this strategy, among the 9
RhoA-GEFs tested, we found that depletion of 5 RhoA-GEFs (Arhgef12, Arhgef2, Arhgef17, Arhgef11, and Arhgef18) affected the activation of RhoA in MA-SMCs (Table 2) The potential tissue-restricted expression of Rho-GEFs obviously raised the possibility of selective targeting of tissue-specific GEFs for therapeutic use, in particular in the context of cardiovascular diseases. From the expression profiles established in arteries, heart, skeletal muscle and brain, we show that, except obscurin expression that is restricted to heart and striated muscle, there is no tissue-specific RhoA-GEFs, neither in arteries, nor in the three other tissues analyzed. However, we highlighted an arterial RhoA-GEF expression profile, relatively homogenous in rat and human arteries analyzed, that differs from those observed in the heart, skeletal muscle and brain. In addition, the expression level of RhoA-GEFs in arteries is higher than that observed in the three other tissues. This could reflect the plasticity of arterial smooth muscle cells and their extraordinary capacity to undergo reversible phenotypic changes in response to changes in environment and functional requirements (9) .
Unlike other muscle cells such as cardiac and skeletal myocytes, smooth muscle cells do not terminally differentiate. They thus retain the ability to switch from quiescent to proliferating cells, from static to migrating cells and from contractile to synthetic cells (28) . All these processes are regulated by Rho-dependent mechanisms, under the control of numerous upstream signals and distinct signaling pathways (17) . Both the diversity of RhoA-GEFs expressed in the media of arteries and their relatively high level of expression may account for the wide spectrum of possible functions that vascular smooth muscle cells can provide.
Although the functional roles of the RhoA-GEFs expressed in arteries is unknown for most of them, it should be noticed that RhoA-GEFs shown to be involved in vasoconstrictorsinduced RhoA signaling activation are found among the 11 most expressed RhoA-GEFs. This includes p63-RhoGEF, described to link G q/11 to RhoA activation by Ang II, phenylephrine and ET-1 (23, 38) and Lbc that mediates 5-HT-induced RhoA activation in vascular smooth muscle cells (1) . The three RGS-RhoGEF Arhgef1, Arhgef11 and Arhgef12 are also part of these RhoA-GEFs. In the three arteries studied, Arhgef12 is the most expressed, Arhgef1 is intermediate and Arhgef11 is the less expressed, in agreement with that previously described in mouse mesenteric arteries (37) . Arhgef12 is involved in G 12 /G 13 Arhgef17 (Grinch) and Arhgef18 (p114-RhoGEF) have been both described as Rho-GEFs activated by G βγ subunits of trimeric G proteins, Arhgef17 is a specific RhoA-GEF while Arhgef18 can activate Rac1 and RhoA (25, 31 ).
This study thus shows that, although there is no arterial specific RhoA-GEF, human and rat arteries display a specific profile of RhoA-GEFs expression. Activation of RhoA/Rho kinase signaling generates a negative feed-back loop on the expression of a group of 9 RhoAGEFs expressed in VSMCs, including Arhgef1, Arhgef2, Arhgef11, Arhgef12, Arhgef17 and Arhgef18, involved in the activation of RhoA by vasoconstrictors. This regulatory mechanism 
